Anzeige
Mehr »
Donnerstag, 08.01.2026 - Börsentäglich über 12.000 News
Steht diese NASDAQ-Biotech-Aktie jetzt vor einer seltenen Kaufgelegenheit?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41C58 | ISIN: CA09076M2004 | Ticker-Symbol: 5LB0
Frankfurt
08.01.26 | 08:14
0,127 Euro
-16,45 % -0,025
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOVAXYS TECHNOLOGY CORP Chart 1 Jahr
5-Tage-Chart
BIOVAXYS TECHNOLOGY CORP 5-Tage-Chart
RealtimeGeldBriefZeit
0,1140,17112:07

Aktuelle News zur BIOVAXYS TECHNOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
BIOVAXYS TECHNOLOGY Aktie jetzt für 0€ handeln
FrStocks in Play: BioVaxys Technology Corp23
31.12.25BioVaxys Technology Corp.: 2025 Corporate Review7
18.12.25Biovaxys Technology Corp (2): Biovaxys posts phase 1 MVP-S breast cancer data9
17.12.25BioVaxys reports positive phase 1 results for breast cancer therapy12
17.12.25BioVaxys Technology Corp.: BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer168Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology...
► Artikel lesen
15.12.25Biovaxys Technology Corp (2): Biovaxys adds Stanford as scientific adviser9
15.12.25Stocks in Play: BioVaxys Technology Corp2
15.12.25BioVaxys Technology Corp.: BioVaxys Strengthens Scientific Team with Addition of Former IMV Vice President of R&D5
25.11.25BioVaxys Technology Corp. Closes Debt Settlement Transaction12
20.11.25Stocks in Play: BioVaxys Technology Corp8
20.11.25Biovaxys Technology Corp (2): Biovaxys Technology closes $1.92-million financing5
19.11.25BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement2
31.10.25Biovaxys Technology Corp (2): Biovaxys Technology increases financing to $2-million19
30.10.25BioVaxys Technology Corp.: BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M360// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Oct. 30, 2025 /PRNewswire/ -- BioVaxys Technology...
► Artikel lesen
28.10.25Biovaxys Technology Corp (2): Biovaxys converts $125,000 debentures to shares3
28.10.25BioVaxys Technology Corp.: BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES228// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Oct. 28, 2025 /PRNewswire/ -- BioVaxys Technology Corp....
► Artikel lesen
22.10.25Biovaxys Technology Corp (2): Biovaxys holders elect to convert debentures12
22.10.25BioVaxys Technology Corp.: BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES319NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC, Oct. 22, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:...
► Artikel lesen
21.10.25BioVaxys Technology Corp.: BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES AND GRANT OF STOCK OPTIONS467// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Oct. 20, 2025 /PRNewswire/ -- BioVaxys Technology Corp....
► Artikel lesen
15.10.25Biovaxys Technology Corp (2): Biovaxys licensee SpayVac talks research results6
Weiter >>
59 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2